🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT06724939
Active, not recruiting Not applicable

Clinical Evaluation of Self-Adhesive Bulk-Fil Hybrid Composite in Primary Molars

NCT06724939 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2022-09-12
Last updated
2024-12-09

Condition(s) studied

Occlual CariesProximal Caries

Investigational drug(s) / intervention(s)

self-adhesive bulk-fill resin composite

self-adhesive bulk-fill resin composite: surefil one self-adhesive bulk-fill composite

Study summary

This study will evaluate the clinical performance of self-adhesive bulk-fill composite resin in the restoration of occlusal and occluso-proximal lesions in primary molars with hypothesis that there is no difference in the clinical performance of self-adhesive bulk-fill composite and traditional bulk-fill composite with adhesive over one year observation period

Eligibility

Sex
ALL
Min age
4 Years
Max age
6 Years
Healthy volunteers
Accepted
Inclusion Criteria: * • Children with bilateral simple occlusal or occluso-proximal caries in the lower second primary molars. * Generally healthy children with no systemic disease. * Cooperative children with a behavior rating of 3 or 4 according to the Frankl Behavior Rating Scale. Exclusion Criteria: * Pulp exposure or indication for endodontic treatment or extraction. * Teeth with symptoms such as spontaneous pain, swelling, infection, fistulae, abscesses or tenderness on percussion. * Parents who weren't available for periodic follow up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sara Mahmoud Abd El-Razzak Al Mansurah Egypt

More Mansoura University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06724939 on ClinicalTrials.gov ↗ ← All trials in Egypt